Scarica l'app Stockscreener
0.455
2.39%
0.0106
Silo Pharma Inc Borsa (SILO) Ultime notizie
Silo Pharma's (NASDAQ:SILO) Groundbreaking Therapies Could Change The Treatment Landscape For PTSD, Fibromyalgia, MS & Alzheimer’s - simplywall.st
Silo Pharma advances PTSD treatment with new drug-device study By Investing.com - Investing.com South Africa
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 - GlobeNewswire
Silo Pharma stock plunges to 52-week low of $0.47 By Investing.com - Investing.com Canada
Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug - Seeking Alpha
SiloPharma (SILO) Advances SPC-15 with New Drug-Device Study Agreement | SILO Stock News - GuruFocus
Silo Pharma Collaborates With Resyca for Drug-Device Study of PTSD Drug SPC-15 - marketscreener.com
Silo Pharma advances PTSD treatment with new drug-device study - Investing.com Australia
Breakthrough PTSD Treatment: Silo Pharma's Brain-Targeting Drug Delivery System Heads to FDA - Stock Titan
Silo Pharma Announces Closing of $2 Million Public Offering - GlobeNewswire
Silo Pharma Completes Public Offering, Raises $1.56 Million - TipRanks
Silo Pharma, Inc. Completes Public Offering Raising Approximately $2 Million - Nasdaq
Silo Pharma Announces Closing Of $2 Million Public Offering - marketscreener.com
SEC Form 424B4 filed by Silo Pharma Inc. - Quantisnow
Silo Pharma sets public offering at $0.60 per share and warrant - Investing.com Nigeria
SiloPharma (SILO) Sets $2 Million Public Offering with Warrants - GuruFocus
Silo Pharma Announces Pricing of $2 Million Public Offering - The Manila Times
Silo Pharma, Inc. Prices Public Offering of 3,333,338 Shares with Associated Warrants - Nasdaq
Silo Pharma Announces $2M Offering with 5-Year Warrants: Complete Details of Latest Financing Round - Stock Titan
Silo Pharma advances in PTSD nasal therapy trials By Investing.com - Investing.com Canada
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment - Asianet Newsable
Silo Pharma (SILO) Partners with Veloxity Labs for Key Drug Stud - GuruFocus
Silo Pharma advances PTSD treatment study with Veloxity Labs By Investing.com - Investing.com Canada
Silo Pharma (SILO) Partners with Veloxity Labs for Key Drug Study | SILO Stock News - GuruFocus
Silo Pharma advances PTSD treatment study with Veloxity Labs - Investing.com Australia
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 - The Manila Times
Breakthrough Intranasal PTSD Drug Heads to FDA: Silo Pharma Partners With Veloxity for Critical IND Studies - Stock Titan
Silo Pharma (SILO) Advances PTSD Treatment with New Study Agreem - GuruFocus
Silo Pharma advances in PTSD nasal therapy trials - Investing.com
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories - The Manila Times
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human - GlobeNewswire
Columbia-Licensed PTSD Drug Nears Human Trials: Silo Pharma's Novel Intranasal Treatment Hits Key Milestone - Stock Titan
Upcoming Events - FinancialContent
SILO Stock Price and Chart — NASDAQ:SILO - TradingView
Silo Pharma, Inc. (NASDAQ:SILO) Shares Sold by Renaissance Technologies LLC - Defense World
Contrasting Silo Pharma (SILO) and Its Competitors - Defense World
Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study - Nasdaq
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models - AOL.com
Silo Pharma stock hits 52-week low at $0.76 amid market challenges - Investing.com Australia
SILO Pharma Achieves Milestone with Promising Preclinical Results for SP-26 | SILO Stock News - GuruFocus
Silo Pharma reports positive preclinical results for SP-26 - Investing.com
Silo Pharma Announces Positive Preclinical Results for SP-26, a Novel Extended-Release Ketamine Implant for Fibromyalgia - Nasdaq
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study - marketscreener.com
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewswire
Revolutionary Ketamine Implant Could Replace Opioids for Fibromyalgia Treatment, Study Shows - Stock Titan
A Guide To The Risks Of Investing In SILO Pharma Inc (SILO) - knoxdaily.com
The Significance of Moving Averages in SILO Pharma Inc Inc. (SILO) Price Performance - investchronicle.com
SILO Pharma Inc (SILO) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):